What causes diminished ovarian reserve, and which causes are addressable?
Diminished ovarian reserve has multiple causes, and distinguishing between them determines what, if anything, can be done to change the picture. The primary biological cause, age-related follicular depletion, is not reversible. Several secondary contributors are addressable.
Causes of DOR by addressability:
Not directly reversible:
- Age-related decline in follicular pool: women are born with a finite number of follicles that decline continuously from birth onward. This decline accelerates after age 35 and is not reversible through any current intervention.
- Genetic factors: certain genetic variants, including FMR1 premutation (associated with fragile X syndrome) and Turner syndrome mosaicism, are associated with premature follicular depletion independent of age.
- Prior ovarian surgery: removal of ovarian cysts, endometriomas, or other surgical interventions can reduce the ovarian follicular pool directly if ovarian tissue was removed or damaged during the procedure.
- Prior chemotherapy or radiation: gonadotoxic treatments can permanently reduce follicular reserve in proportion to the dose and type of treatment received.
Potentially addressable:
- Vitamin D deficiency: AMH production by granulosa cells is regulated in part by vitamin D. Deficiency suppresses AMH. Correcting vitamin D to sufficiency has produced modest AMH increases in research studies.
- Thyroid dysfunction and autoimmunity: thyroid antibodies are associated with reduced AMH and accelerated follicular depletion. Thyroid optimization may slow the rate of decline.
- Systemic inflammation: elevated inflammatory markers correlate with lower AMH in reproductive-age women. Anti-inflammatory interventions may partially reverse this suppression.
A 2020 review in the Journal of Clinical Medicine found that vitamin D sufficiency was significantly associated with higher AMH in reproductive-age women independent of age, supporting the clinical relevance of correcting vitamin D before accepting a DOR diagnosis as fixed.
Can vitamin D supplementation actually raise AMH?
Yes, in some women and to a modest degree. The relationship between vitamin D and AMH is biological: granulosa cells express vitamin D receptors, and vitamin D regulates the expression of genes involved in AMH production. When vitamin D is deficient, granulosa cell function is suboptimal and AMH production is suppressed below the level the available follicular pool would otherwise produce.
What the research shows:
- A 2019 randomized trial in the Journal of Clinical Endocrinology and Metabolism found that vitamin D supplementation in deficient women (below 20 ng/mL) produced significant AMH increases at 3 months compared to placebo, with the magnitude of increase correlating with the degree of deficiency correction.
- The AMH increases observed were modest: typically in the range of 0.3 to 0.8 ng/mL above baseline in deficient women corrected to sufficiency. This is not a dramatic reversal of DOR but may be clinically meaningful for a woman whose pre-correction AMH placed her just below a threshold relevant to treatment decisions.
- Women who begin with adequate vitamin D levels (above 40 ng/mL) do not show significant additional AMH increases from further supplementation. The benefit is specific to correction of deficiency.
The fertility-relevant target for vitamin D is 50 to 80 ng/mL, substantially above the standard sufficiency threshold of 20 ng/mL. A woman with vitamin D at 22 ng/mL is technically sufficient by standard criteria but is likely not at the level that optimally supports granulosa cell function and AMH production.
Correction of vitamin D from a low baseline to fertility-optimal levels typically takes 8 to 12 weeks at supplementation doses of 3,000 to 5,000 IU daily. Testing before and after correction is the most direct way to assess whether AMH responds.
What is the relationship between thyroid health and ovarian reserve?
Thyroid dysfunction, particularly autoimmune thyroid disease characterized by elevated TPO antibodies, is associated with both reduced AMH and accelerated follicular depletion. The relationship operates through two mechanisms: direct effects of thyroid hormone on follicular development and the systemic immune activation that thyroid autoimmunity produces.
How thyroid health affects ovarian reserve:
- Thyroid hormone and folliculogenesis: thyroid hormone receptors are expressed in granulosa cells and oocytes. Thyroid hormone supports normal follicular development, and hypothyroidism, even subclinical, slows follicular growth and reduces the hormonal signals that sustain developing follicles.
- TPO antibodies and follicular environment: elevated TPO antibodies create systemic immune activation that reaches the ovarian environment and may accelerate follicular atresia (the natural process of follicle death). Women with elevated TPO antibodies consistently show lower AMH than antibody-negative women of the same age in research studies.
- Rate of reserve decline: longitudinal studies suggest that women with thyroid autoimmunity show faster AMH decline over time than antibody-negative women. Thyroid optimization may slow but not halt this accelerated decline.
The practical implication is that a DOR diagnosis in a woman with undetected or undertreated thyroid autoimmunity may partly reflect the thyroid picture rather than the true follicular reserve. Investigating and addressing thyroid status before accepting a DOR reading as definitive is clinically supported.
A 2021 study in Thyroid found that women with subclinical hypothyroidism and elevated TPO antibodies had AMH values approximately 30 percent lower than euthyroid antibody-negative women of the same age, with partial normalization following thyroid optimization in a prospective follow-up cohort.
What does premature ovarian insufficiency mean, and is it different from DOR?
Premature ovarian insufficiency (POI) is a distinct diagnosis characterized by irregular or absent periods, elevated FSH, and reduced or absent follicular activity in women under 40, typically defined as FSH above 25 to 40 mIU/mL on two tests four weeks apart. POI reflects a more severe state of ovarian function reduction than DOR and carries different clinical implications.
Key distinctions between DOR and POI:
- DOR: reduced ovarian reserve for age, often defined as AMH below 1.0 ng/mL or FSH above 10 to 12 mIU/mL on cycle day 3. Ovulation typically still occurs, though less consistently. Natural conception and IVF response are reduced but not eliminated.
- POI: ovarian function has declined to a level where regular ovulation is absent or inconsistent, FSH is substantially elevated, and estrogen may be low. Natural conception is possible but occurs in only approximately 5 percent of women with POI, typically through intermittent spontaneous follicular activity.
POI in women under 40 warrants investigation for specific causes including:
- Autoimmune adrenal disease (associated in approximately 4 percent of POI cases)
- FMR1 premutation (fragile X carrier status), which is the most common known genetic cause of POI
- Turner syndrome mosaicism
- Prior autoimmune conditions including autoimmune thyroid disease, type 1 diabetes, and rheumatoid arthritis
A POI diagnosis in a woman under 40 should prompt genetic and autoimmune investigation before treatment decisions are made, as identifiable causes may have implications for both treatment approach and family members.
What is the most useful response to a DOR diagnosis?
The most useful response to a DOR diagnosis combines three simultaneous tracks: investigating for addressable contributors to the low AMH reading, optimizing egg quality in the eggs that remain, and making informed decisions about treatment timing that honestly account for the time pressure low reserve creates.
Track 1: Investigate addressable contributors
- Test vitamin D (25-OH), TSH with Free T3, Free T4, and TPO antibodies, and hs-CRP alongside the next AMH retest
- Review recent oral contraceptive use: if discontinued within six months, plan a retest after that interval
- Assess for recent acute physiological stressors that may have temporarily suppressed AMH
Track 2: Optimize egg quality in the eggs that remain
- Begin CoQ10 supplementation at 400 to 600 mg daily in ubiquinol form
- Implement anti-inflammatory dietary changes and blood sugar stabilization
- Correct vitamin D to the fertility-optimal target of 50 to 80 ng/mL
- Address thyroid function if suboptimal
Track 3: Make informed treatment timing decisions
- Discuss with your RE the specific implications of your AMH and antral follicle count for IVF response and the number of likely retrieval cycles available
- Consider egg or embryo banking across multiple cycles if reserve allows multiple retrievals
- Identify the decision point at which donor egg consideration becomes appropriate for your specific clinical picture
Research published in Human Reproduction found that women with DOR who pursued all three tracks simultaneously had significantly better informed treatment decisions and improved clinical outcomes compared to women who received DOR diagnoses without systematic investigation of contributors or egg quality support.
The The Fertility Intelligence Hub Perspective
DOR told me I had fewer eggs. It did not tell me what those eggs were capable of.
When I received my DOR diagnosis, the conversation felt like it was already pivoting toward donor eggs before I had asked a single question about what was driving the number.
What I eventually learned is that AMH tells you one thing: how many small developing follicles are present right now. It does not tell you whether your vitamin D is suppressing the reading. It does not tell you whether your thyroid antibodies are accelerating follicular depletion. It does not tell you what the eggs you have are capable of in a well-supported physiological environment.
Investigating and addressing those factors does not restore depleted reserve. But for some women, it reveals more reserve than the initial number suggested. And for all women with DOR, it changes what each remaining egg has to work with during its 90-day maturation window.
I am not suggesting that DOR is not real, or that every woman with low AMH will conceive with her own eggs. That would not be honest. What I am saying is that the response to a DOR diagnosis deserves more than a single conversation about whether to proceed with donor eggs. It deserves a full investigation of what is driving the number and what can be done about the eggs that remain.
